Tolmar International sale of its Australian arm

Henslow congratulates global pharmaceuticals group Tolmar International on the sale of its Australian arm, Tolmar Australia Pty Limited, a specialised uro-oncology company, to Mundipharma. Tolmar Australia holds exclusive distribution rights for the oncology medication Eligard® (leuprorelin acetate), a leading PBS-reimbursed prostate cancer therapeutic in Australia and New Zealand.

The acquirer Mundipharma is a global pharmaceuticals company with a large presence in Australia, and the acquisition will add to their existing Australian oncology business.

Henslow acted as Financial Advisor to Tolmar International.

This transaction further demonstrates Henslow’s strong pharmaceutical and healthcare industry expertise.

Recent posts

Looking for investment opportunities?

Backed and vetted by Henslow, unlock a selection of unique investment opportunities. Register an account to get started.

Investment hub